Περίληψη:
Objective: It is not known whether patients with atrial fibrillation (AF) with ischemic stroke despite oral anticoagulant therapy are at increased risk for further recurrent strokes or how ongoing secondary prevention should be managed. Methods: We conducted an individual patient data pooled analysis of 7 prospective cohort studies that recruited patients with AF and recent cerebral ischemia. We compared patients taking oral anticoagulants (vitamin K antagonists [VKA] or direct oral anticoagulants [DOAC]) prior to index event (OACprior) with those without prior oral anticoagulation (OACnaive). We further compared those who changed the type (ie, from VKA or DOAC, vice versa, or DOAC to DOAC) of anticoagulation (OACchanged) with those who continued the same anticoagulation as secondary prevention (OACunchanged). Time to recurrent acute ischemic stroke (AIS) was analyzed using multivariate competing risk Fine-Gray models to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). Results: We included 5,413 patients (median age = 78 years [interquartile range (IQR) = 71-84 years]; 5,136 [96.7%] had ischemic stroke as the index event, median National Institutes of Health Stroke Scale on admission = 6 [IQR = 2-12]). The median CHA2DS2-Vasc score (congestive heart failure, hypertension, age≥ 75 years, diabetes mellitus, stroke/transient ischemic attack, vascular disease, age 65-74 years, sex category) was 5 (IQR = 4-6) and was similar for OACprior (n = 1,195) and OACnaive (n = 4,119, p = 0.103). During 6,128 patient-years of follow-up, 289 patients had AIS (4.7% per year, 95% CI = 4.2-5.3%). OACprior was associated with an increased risk of AIS (HR = 1.6, 95% CI = 1.2-2.3, p = 0.005). OACchanged (n = 307) was not associated with decreased risk of AIS (HR = 1.2, 95% CI = 0.7-2.1, p = 0.415) compared with OACunchanged (n = 585). Interpretation: Patients with AF who have an ischemic stroke despite previous oral anticoagulation are at a higher risk for recurrent ischemic stroke despite a CHA2DS2-Vasc score similar to those without prior oral anticoagulation. Better prevention strategies are needed for this high-risk patient group. © 2020 The Authors.
Συγγραφείς:
Seiffge, D.J.
De Marchis, G.M.
Koga, M.
Paciaroni, M.
Wilson, D.
Cappellari, M.
Macha, K.
Tsivgoulis, G.
Ambler, G.
Arihiro, S.
Bonati, L.H.
Bonetti, B.
Kallmünzer, B.
Muir, K.W.
Bovi, P.
Gensicke, H.
Inoue, M.
Schwab, S.
Yaghi, S.
Brown, M.M.
Lyrer, P.
Takagi, M.
Acciarrese, M.
Jager, H.R.
Polymeris, A.A.
Toyoda, K.
Venti, M.
Traenka, C.
Yamagami, H.
Alberti, A.
Yoshimura, S.
Caso, V.
Engelter, S.T.
Werring, D.J.
RAF, RAF-DOAC, CROMIS-2, SAMURAI, NOACISP, Erlangen,
Verona registry collaborators
Λέξεις-κλειδιά:
acenocoumarol; anticoagulant agent; antithrombocytic agent; antivitamin K; apixaban; dabigatran; edoxaban; heparin; phenprocoumon; rivaroxaban; warfarin, aged; anticoagulant therapy; Article; atrial fibrillation; brain hemorrhage; brain ischemia; CHA2DS2-VASc score; cohort analysis; comparative study; confidence interval; congestive heart failure; controlled study; diabetes mellitus; female; follow up; hazard ratio; high risk patient; human; hypertension; major clinical study; male; mortality; multicenter study; multivariate analysis; National Institutes of Health Stroke Scale; observational study; outcome assessment; post hoc analysis; priority journal; prospective study; recurrence risk; risk assessment; secondary prevention; transient ischemic attack; treatment failure; vascular disease
